The Lift Line

“A disease that is no longer counted is not a disease that is gone.”

Why This Editorial Matters for Your Exam

The Hindu’s lead editorial of 7 October 2026, “Break the chain”, examines why India, which declared leprosy eliminated as a public health problem two decades ago, is now falling behind the targets of its National Strategic Plan (NSP) and Roadmap for Leprosy 2023-2027. It follows the paper’s report on the programme’s 2025-26 annual report, which we covered in a 4 October deep dive on child leprosy cases.

The editorial is useful well beyond leprosy. It is a case study in how health indicators can mislead: a programme can hit its prevalence target while the disease keeps spreading. The same lesson applies to tuberculosis, malaria and kala-azar, and to any target that measures what is easy to count rather than what matters.

GS Paper 2: Issues relating to development and management of the social sector and services relating to health; government policies and interventions; vulnerable sections. GS Paper 1: Social issues (stigma, marginalised groups). Essay: “What gets measured gets managed.”

Background and Context

Leprosy in brief

Feature Detail
Cause Mycobacterium leprae, a slow-growing bacterium
What it affects Skin, peripheral nerves, eyes and the lining of the upper respiratory tract
Spread Droplets from the nose and mouth during prolonged close contact with an untreated patient
Incubation Long, often several years, which lets infection spread silently
Cure Multidrug therapy (MDT), free under the national programme
Disability grades Grade 1: loss of sensation; Grade 2 (G2D): visible deformity such as clawed hands, foot drop or eye damage

How India got here

Period Development
1955 National Leprosy Control Programme launched
1983 Renamed the National Leprosy Eradication Programme (NLEP); MDT introduced
December 2005 National prevalence below 1 per 10,000: “elimination as a public health problem” declared
After 2005 Leprosy services folded into general health services
Early 2010s Disability among new cases rises; active case-finding campaigns begin
30 January 2023 NSP and Roadmap for Leprosy 2023-27 launched in 2023, on Anti-Leprosy Day
2025-26 NLEP report: targets for incidence, child cases and disability all missed

The two measures that matter

  • Prevalence counts patients on treatment at a point in time. It falls quickly when treatment is shorter, even if new infections continue.
  • Incidence counts new cases in a year. Rising child incidence and disability at diagnosis are the clearest signs that transmission continues and that diagnosis is late: a child with leprosy must have been infected recently, by someone in the community.

The NSP defines a district as having interrupted transmission when it reports no new indigenous child cases for five consecutive years.

The Analysis

1. The complacency after 2005. The editorial’s sharpest point is historical. Once prevalence fell below 1 per 10,000 and India declared that it had eliminated leprosy as a public health problem, the government “became complacent” and folded the dedicated surveillance programme into the general health system. Specialised staff and skills thinned. At the same time, shorter MDT regimens reduced the period for which patients stayed formally registered. The result was a statistical illusion: prevalence fell while transmission continued.

2. The warning signs that followed. Disability due to leprosy began to rise in the early 2010s, which meant patients were reaching care late, with nerve damage already done. This prompted door-to-door screening. The editorial welcomes the NSP’s focus on cutting transmission, in line with the WHO’s strategy, as the right correction.

3. Children are the measure. India’s children accounted for around 46 per cent of all child cases reported worldwide in 2025. Because child cases reveal recent transmission, the editorial says the child-focused and adult-focused efforts must move in tandem.

4. An uneven map. The decline has been highly uneven. Chhattisgarh, Jharkhand, Odisha and Maharashtra carry a disproportionate share of the national burden. Only 148 districts have achieved interruption of transmission, and that is pending field verification, against a projected 300.

5. The effort is real. The editorial records the scale of work in 2025-26:

Activity Scale
People screened in highly endemic areas More than 70 crore
Cases detected in that screening 24,367
Suspected cases flagged by ASHA workers Nearly 40 lakh
Cases confirmed from those 48,027
Contacts given single-dose rifampicin as post-exposure prophylaxis 91.1% of about 16.9 lakh

The government has also put digital surveillance in place and is considering the MIP vaccine to speed up clearance of the pathogen in patients judged highly infectious.

6. The gap in care. Research shows that many patients already have nerve damage by the time they seek care, largely because of stigma. Many clinicians are unfamiliar with the disease and misdiagnose it as a skin condition. Both delay treatment, and every month of delay is a month of possible spread and of irreversible damage.

7. The prescription. The editorial makes three demands:

  • Double down on interrupting transmission and treat prevalence as a secondary outcome.
  • Resist the temptation to ease detection or revise targets. Incidence overshot projections by 41 per cent, child incidence by 91.6 per cent and the grade-2 disability rate by 34 per cent. The answer is to redouble investment to meet the existing 2026-27 projections, not to move the goalposts.
  • Concentrate effort on the places and social settings where late diagnosis and transmission remain entrenched.

Data and Institutions Vault

Prelims-grade facts:

The 2025-26 picture (NLEP report, as reported by The Hindu):

  • Districts with interruption of transmission: 148 (pending field verification), against 300 projected.
  • Overshoot against projections: incidence 41%, child incidence 91.6%, grade-2 disability rate 34%.
  • New cases 91,783; child cases 3,832 (target 2,000); G2D rate 1.34 per million population.
  • India’s share of the world’s child cases in 2025: about 46%.
  • High-burden States named: Chhattisgarh, Jharkhand, Odisha, Maharashtra.

Tools of the programme:

  • Active case detection and door-to-door screening; ASHA-led referral.
  • SDR-PEP: single-dose rifampicin post-exposure prophylaxis for contacts.
  • Nikusth 2.0: web portal for case reporting.
  • MIP (Mycobacterium indicus pranii): an India-developed immunomodulator, under consideration for highly infectious patients.
  • Sparsh Leprosy Awareness Campaign and Anti-Leprosy Day on 30 January, Mahatma Gandhi’s death anniversary, a historic link to his care for leprosy patients.

Policy framework:

  • NSP and Roadmap for Leprosy 2023-27: zero transmission at district level by 2027; zero disability among new child cases; zero stigma.
  • WHO Global Leprosy Strategy 2021-2030, “Towards zero leprosy”.
  • “Elimination as a public health problem”: prevalence below 1 per 10,000; India reached it in 2005.

⚠️ Watch the trap: Elimination is not eradication. India “eliminated leprosy as a public health problem” in 2005 by bringing prevalence below 1 per 10,000; the disease was never eradicated, and India still reports the most new cases in the world. Interruption of transmission is a third, higher bar: no new indigenous child cases for five consecutive years in a district.

The Debate

For the editorial’s view. The numbers are hard to argue with. When child incidence runs at almost double the projection and disability at diagnosis rises, transmission is continuing and diagnosis is late. Prevalence, which looks good, hides both. Easing detection to make the figures look better would repeat the mistake of 2005. Keeping the existing projections forces the system to find and treat the hidden cases.

The other side. Part of the overshoot is an artefact of better searching. When the programme screens 70 crore people and follows up 40 lakh suspected cases, it will find cases that would otherwise have gone unrecorded. Higher numbers in the short run are the expected result of active case-finding, and they may be a sign of success. There is also a risk the editorial does not discuss: targets set too tightly can encourage under-reporting at district level, the opposite of what the programme wants.

The balanced verdict. Both points can be true. Rising counts from intense screening are welcome, but child cases and G2D at diagnosis are not easily explained by better searching alone: they point to transmission and delay. The right response is to keep both the search intensity and the targets, while judging districts by the trend in child cases over several years rather than a single year’s count.

How to Think About This

Choose the indicator that matches the goal. Prevalence measures the burden on the health system; incidence measures whether the disease is spreading. A programme that wants to end a disease must track the second. Use this in any answer on disease control: India’s TB programme similarly moved from case notification to incidence estimates, and malaria elimination is judged by indigenous transmission.

Vertical versus horizontal programmes. Folding a disease-specific programme into general health services saves money and strengthens primary care, but can erode specialised skills when a disease becomes rare. The lesson is not to avoid integration, but to keep surveillance and expertise alive after a disease stops being visible.

Stigma is an epidemiological factor. Fear of social rejection makes patients hide symptoms, which delays treatment and extends the period in which they can infect others. Anti-stigma work is therefore not only a rights issue but a disease-control tool.

Diagram-in-Words

Argument map

Break the Chain: why leprosy still spreads after 2005

The editorial’s argument, from the 2005 milestone of elimination as a public health problem to the goal it asks for, interrupting transmission.

2005: elimination declared prevalence below 1 per 10,000 Complacency dedicated surveillance folded into general health services; skills thinned Shorter MDT patients stayed registered for less time, so prevalence fell faster A statistical illusion prevalence fell while transmission continued Disability rose from the early 2010s: patients reaching care late, nerves already damaged Children infected India had around 46% of all child cases reported worldwide in 2025 Targets missed incidence 41%, child incidence 91.6%, G2D 34% above projections the warning signs Goal: break transmission 148 districts so far, pending verification, against 300 projected Transmission first treat prevalence as a secondary outcome Keep the targets redouble investment to meet the 2026-27 projections; do not ease detection Go where it hides places and social settings where late diagnosis persists the editorial’s three demands
The chain of the argument: a fall in prevalence after 2005 hid continuing transmission, the warning signs now show it, and the editorial’s answer is to judge the programme by transmission and work harder to break it.
✍️ Mains Answer Framework
Question

India's leprosy programme achieved elimination as a public health problem in 2005, but transmission continues. Examine why, and suggest how the goal of interrupting transmission by 2027 can be met. (150 words)

In 2005 India brought leprosy prevalence below 1 per 10,000 and was declared to have eliminated it as a public health problem. Two decades later India still detects about 90,000 new cases a year, and the National Strategic Plan and Roadmap for Leprosy 2023-27 aims at a harder target: interrupting transmission at the district level by 2027.

Why transmission continued: after 2005, vertical leprosy surveillance was merged into general health services and expertise thinned; shorter multidrug therapy reduced the time patients stayed on registers, so prevalence fell even as infection spread; and stigma and misdiagnosis as a skin condition delayed care until nerve damage set in. Where things stand: in 2025-26 only 148 districts had interrupted transmission against a projected 300; incidence overshot projections by 41 per cent, child incidence by 91.6 per cent and the grade-2 disability rate by 34 per cent; India accounted for about 46 per cent of the world’s child cases in 2025.
What is working: screening of over 70 crore people in endemic areas, ASHA-led detection, and single-dose rifampicin for 91.1 per cent of 16.9 lakh contacts.

India should measure success by transmission, not prevalence; keep detection at full intensity without revising targets; train clinicians; tackle stigma; and concentrate resources in high-burden districts such as those of Chhattisgarh, Jharkhand, Odisha and Maharashtra.

Interview Angle

"India declared leprosy eliminated as a public health problem in 2005, yet it still reports the largest number of new cases in the world. Was the 2005 declaration a mistake?"

Takeaway Box

  • Thesis: measure leprosy control by transmission, not prevalence, and do not move the targets.
  • History: elimination as a public health problem in 2005; complacency and integration into general services followed; disability rose in the early 2010s.
  • Status (2025-26): 148 districts with interrupted transmission against 300 projected; incidence 41%, child incidence 91.6% and G2D 34% above projections.
  • Effort: over 70 crore screened; nearly 40 lakh suspected cases flagged by ASHAs; rifampicin PEP for 91.1% of 16.9 lakh contacts.
  • Gaps: stigma, late care, misdiagnosis as a skin disease; burden concentrated in Chhattisgarh, Jharkhand, Odisha, Maharashtra.

Revision Flowchart

Revision flowchart

Leprosy in India and the 2027 goal

Covers the disease, the milestones from 1955 to 2023, the 2025-26 data, the programme’s tools, why leprosy persists and the exam angles.

Leprosy in India: break the chain by 2027 Judge the programme by transmission, not prevalence (The Hindu editorial, GS2 health) The disease Cause Mycobacterium leprae, a slow-growing bacterium; attacks skin and peripheral nerves Spread droplets in prolonged close contact; incubation often several years Cure multidrug therapy (MDT), free under the national programme Milestones 1955 National Leprosy Control Programme 1983 renamed NLEP; MDT introduced 2005 prevalence below 1 per 10,000: elimination as a public health problem 2023 NSP and Roadmap for Leprosy 2023-27, launched on Anti-Leprosy Day 2025-26 data NLEP report Districts 148 with interrupted transmission (pending verification) vs 300 projected Cases 91,783 new; 3,832 child cases against a target of 2,000 Overshoot incidence 41%, child incidence 91.6%, G2D rate 34% above projections World share about 46% of all child cases reported worldwide in 2025 Tools Screening more than 70 crore people screened in highly endemic areas; 24,367 cases detected ASHA referral nearly 40 lakh suspected cases flagged; 48,027 confirmed SDR-PEP single-dose rifampicin for 91.1% of about 16.9 lakh contacts MIP vaccine India-developed immunomodulator, under consideration Nikusth 2.0 web portal for case reporting Why it persists Complacency dedicated surveillance folded into general services after 2005 Stigma patients hide symptoms and reach care with nerve damage Misdiagnosis many clinicians misdiagnose it as a skin condition Uneven map Chhattisgarh, Jharkhand, Odisha and Maharashtra carry a disproportionate share Exam angle Prelims trap elimination is not eradication; interruption is a third, higher bar Interruption no new indigenous child cases for five consecutive years in a district NSP targets zero transmission at district level by 2027; zero disability among new child cases; zero stigma Mains themes prevalence vs incidence; vertical vs horizontal programmes; stigma
Revision flowchart: the whole editorial on one screen. Read each band left to right, then test yourself by covering the facts and recalling them from the headings.

Sources: The Hindu, editorial, 7 October 2026; background: The Hindu, 4 October 2026, DGHS, NLEP

Key Arguments at a Glance

Leprosy prevalence and disability have fallen over the past decade, but continued transmission in many pockets threatens the targets of the National Strategic Plan and Roadmap for Leprosy 2023-2027. The government should make interrupting transmission its primary goal and treat prevalence as secondary, resisting any temptation to ease detection or revise targets.

Supporting
  • After the 2005 declaration of elimination as a public health problem, complacency set in: leprosy surveillance was folded into the general health system, and shorter multidrug regimens let registered prevalence fall while transmission continued.
  • Disability due to leprosy began rising in the early 2010s, which prompted door-to-door screening; the NSP now rightly focuses on cutting transmission, in line with the WHO.
  • India accounted for around 46 per cent of all child leprosy cases reported worldwide in 2025, and the burden is concentrated in Chhattisgarh, Jharkhand, Odisha and Maharashtra.
  • Only 148 districts have achieved interruption of transmission (pending field verification), against a projected 300.
  • Incidence overshot projections by 41 per cent in 2025-26, child incidence by 91.6 per cent and the grade-2 disability rate by 34 per cent.
Counter

Some of the overshoot reflects more intensive case-finding: screening more than 70 crore people and following up nearly 40 lakh suspected cases will find hidden cases, so rising numbers partly mean better detection, not worse control. Targets set too tightly can also push programmes to under-report.

Way Forward

Make interruption of transmission the headline indicator; keep active case-finding and post-exposure prophylaxis at full scale; use digital surveillance; consider the MIP vaccine for highly infectious patients; train clinicians to recognise leprosy early; fight stigma so patients seek care before nerve damage; and concentrate effort on the districts and social settings where late diagnosis and transmission persist.

Cite this page: Break the Chain: Leprosy in India and the 2027 Goal — Ujiyari.com | Free UPSC & State PCS Editorial Analysis